^
Association details:
| Biomarker: | IL22 overexpression |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | entospletinib (GS-9973) (SYK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
Excerpt:
In vivo inhibition of leukemia proliferation with entospletinib monotherapy was observed in RAS-wild-type KMT2A-AFF1, KMT2A-MLLT3, and KMT2A-MLLT1 ALL PDX models with enhanced activity in combination with vincristine chemotherapy in several models.
DOI:
10.3324/haematol.2019.241729
